Low-dose Combination of Mycophenolate Mofetil (MMF) and Tacrolimus (Tac) for Refractory Lupus Nephritis

This study has been completed.
Information provided by (Responsible Party):
Chi Chiu Mok, Tuen Mun Hospital
ClinicalTrials.gov Identifier:
First received: September 15, 2010
Last updated: March 3, 2014
Last verified: March 2014
A trial of combination of two drugs for the treatment of refractory lupus nephritis.

Condition Intervention Phase
Lupus Nephritis
Drug: low dose combination of MMF and Tac
Phase 4

Study Type: Interventional
Study Design: Endpoint Classification: Efficacy Study
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: Low-dose Combination of Mycophenolate Mofetil and Tacrolimus for Refractory Lupus Nephritis: a 12-month Prospective Study

Resource links provided by NLM:

Further study details as provided by Tuen Mun Hospital:

Primary Outcome Measures:
  • Clinical remission rate [ Time Frame: 12 months ] [ Designated as safety issue: No ]

Secondary Outcome Measures:
  • Adverse events [ Time Frame: 12 months ] [ Designated as safety issue: Yes ]
    adverse events experienced by patients as a measure of tolerability

Enrollment: 20
Study Start Date: August 2010
Study Completion Date: February 2013
Primary Completion Date: December 2012 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: Combination treatment
treatment arm
Drug: low dose combination of MMF and Tac
mycophenolate mofetil 500mg BID + tacrolimus 2mg BID
Other Name: Cellcept and Prograf

Detailed Description:
Low-dose combination of mycophenolate mofetil and tacrolimus for refractory lupus nephritis: a 12-month prospective study

Ages Eligible for Study:   18 Years to 80 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  1. Active nephritis documented by renal biopsy within 24 months of entry;
  2. Failure to respond to 2 or more immunosuppressive regimens which consisted of high-dose prednisolone combined with other non-corticosteroid immunosuppressive agents together with ACE inhibitors plus or minus angiotensin receptor blockers (ARB) for at least 4 months for each regimen at the maximally tolerated drug dosages;
  3. Serum creatinine (Scr) less than 200umol/L.

Exclusion Criteria:

  1. Previous intolerance to either MMF/Tac;
  2. Scr >200umol/L;
  3. Informed consent unavailable.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT01203709

Tuen Mun Hospital
Hong Kong, China
Sponsors and Collaborators
Tuen Mun Hospital
Principal Investigator: CC Mok, MD, FRCP Tuen Mun Hospital, Hong Kong China
  More Information

Responsible Party: Chi Chiu Mok, Consultant, Tuen Mun Hospital
ClinicalTrials.gov Identifier: NCT01203709     History of Changes
Other Study ID Numbers: NTWC/CREC/837/10 
Study First Received: September 15, 2010
Last Updated: March 3, 2014
Health Authority: Hong Kong: Ethics Committee

Keywords provided by Tuen Mun Hospital:

Additional relevant MeSH terms:
Lupus Nephritis
Autoimmune Diseases
Connective Tissue Diseases
Immune System Diseases
Kidney Diseases
Lupus Erythematosus, Systemic
Urologic Diseases
Mycophenolate mofetil
Mycophenolic Acid
Antibiotics, Antineoplastic
Antineoplastic Agents
Calcineurin Inhibitors
Enzyme Inhibitors
Immunologic Factors
Immunosuppressive Agents
Molecular Mechanisms of Pharmacological Action
Physiological Effects of Drugs

ClinicalTrials.gov processed this record on May 26, 2016